VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Info & Links
CEO
Shawn K. Singh
Headquarters
343 ALLERTON AVENUE SOUTH SAN FRANCISCO, CA 94080, UNITED STATES
Vistagen Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
60.90M
Enterprise Value
-13.82M
Enterprise Value/EBITDA(ttm)
0.26
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
118.67
Price to Book(mrq)
0.99
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-6777.08%
Profit Margin(ttm)
-7672.35%
Return on Equity(ttm)
-48.12%
Return on Invested Capital(ttm)
-49.87%
Return on Assets(ttm)
-43.80%
Income Statement
Revenue(ttm)
699.00K
Revenue Per Share(ttm)
0.02
Gross Profit(ttm)
699.00K
EBITDA(ttm)3
-52.95M
Net Income Available to Common(ttm)
-47.30M
Diluted EPS(ttm)
-1.48
Share Statistics
Beta (5Y Monthly)
0.77
52-Week Change
-54.93%
S&P 500 52-Week Change
6.35%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
28.86M
Dividend Yield
0.00%
Float4
28.49M
% Held by Insiders
1.29%
% Held by Institutions
78.39%
Balance Sheet
Total Cash(mrq)
88.56M
Total Cash Per Share(mrq)
3.07
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
9.35%
Quick Ratio(mrq)
9.35%
Book Value Per Share(mrq)
2.86
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.04
Free Cash Flow(ytd)
-32.14M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.